1. Home
  2. L vs PODD Comparison

L vs PODD Comparison

Compare L & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loews Corporation

L

Loews Corporation

HOLD

Current Price

$102.75

Market Cap

21.5B

Sector

Finance

ML Signal

HOLD

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$304.59

Market Cap

22.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
L
PODD
Founded
1969
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.5B
22.1B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
L
PODD
Price
$102.75
$304.59
Analyst Decision
Strong Buy
Analyst Count
0
19
Target Price
N/A
$359.00
AVG Volume (30 Days)
817.3K
765.6K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
0.24%
N/A
EPS Growth
N/A
N/A
EPS
6.86
3.45
Revenue
$18,266,000,000.00
$2,521,800,000.00
Revenue This Year
N/A
$32.55
Revenue Next Year
N/A
$20.39
P/E Ratio
$15.00
$88.24
Revenue Growth
6.06
27.11
52 Week Low
$78.98
$230.05
52 Week High
$109.06
$354.88

Technical Indicators

Market Signals
Indicator
L
PODD
Relative Strength Index (RSI) 42.64 40.94
Support Level $103.69 $303.20
Resistance Level $109.06 $317.34
Average True Range (ATR) 1.55 13.12
MACD -0.47 -2.82
Stochastic Oscillator 2.02 3.14

Price Performance

Historical Comparison
L
PODD

About L Loews Corporation

Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: